Lixte Biotechnology Holdings logo
LIXT logo

Lixte Biotechnology HoldingsNasdaqCM:LIXT Stock Report

Market Cap US$3.2m
Share Price
n/a
1Y-39.2%
7D-17.1%
Portfolio Value
View

Lixte Biotechnology Holdings, Inc.

NasdaqCM:LIXT Stock Report

Market Cap: US$3.2m

LIXT Stock Overview

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. More details

LIXT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Lixte Biotechnology Holdings, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lixte Biotechnology Holdings
Historical stock prices
Current Share PriceUS$1.41
52 Week HighUS$4.40
52 Week LowUS$1.31
Beta-0.045
1 Month Change-39.35%
3 Month Change-7.24%
1 Year Change-39.22%
3 Year Change-89.48%
5 Year Change-97.45%
Change since IPO-96.87%

Recent News & Updates

Recent updates

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Feb 08
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

May 05
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Jan 20
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Jul 20
We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Jun 02

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Feb 25
Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Shareholder Returns

LIXTUS BiotechsUS Market
7D-17.1%3.7%1.2%
1Y-39.2%-1.0%23.7%

Return vs Industry: LIXT underperformed the US Biotechs industry which returned -1% over the past year.

Return vs Market: LIXT underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is LIXT's price volatile compared to industry and market?
LIXT volatility
LIXT Average Weekly Movement17.0%
Biotechs Industry Average Movement11.0%
Market Average Movement5.9%
10% most volatile stocks in US Market18.0%
10% least volatile stocks in US Market3.0%

Stable Share Price: LIXT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: LIXT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20054Bas van der Baanlixte.com

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.

Lixte Biotechnology Holdings, Inc. Fundamentals Summary

How do Lixte Biotechnology Holdings's earnings and revenue compare to its market cap?
LIXT fundamental statistics
Market capUS$3.22m
Earnings (TTM)-US$4.00m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LIXT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$4.00m
Earnings-US$4.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.78
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did LIXT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/19 08:16
End of Day Share Price 2025/02/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lixte Biotechnology Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.